Lite Strategy, Inc.

NasdaqCM:LITS Stock Report

Market Cap: US$45.5m

Lite Strategy Past Earnings Performance

Past criteria checks 0/6

Lite Strategy has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 30.7% annually. Revenues have been declining at an average rate of 21.7% per year.

Key information

21.26%

Earnings growth rate

30.26%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-21.75%
Return on equity-48.50%
Net Marginn/a
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Analysis Article Feb 17

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article Dec 30

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Key Insights MEI Pharma to hold its Annual General Meeting on 05 January 2023 CEO Dan Gold's total compensation...
Analysis Article Nov 19

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Celebrations may be in order for MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders, with the analysts delivering a...
Analysis Article May 18

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Mar 26

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

The analysts covering MEI Pharma, Inc. ( NASDAQ:MEIP ) delivered a dose of negativity to shareholders today, by making...
Analysis Article Feb 12

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders today, when the analysts downgraded...
Seeking Alpha Feb 01

MEI Pharma: Another PI3K Delta Progressing To The FDA

MEIP's lead asset is zandelisib, an oral PI3K delta inhibitor. In two studies in Follicular lymphoma, zandelisib has shown strong data. What should concern MEI is the FDA's issue with safety for the entire PI3K delta class.
Analysis Article Dec 02

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

One thing we could say about the analysts on MEI Pharma, Inc. ( NASDAQ:MEIP ) - they aren't optimistic, having just...
Analysis Article Nov 04

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Feb 25

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

We'd be surprised if MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders haven't noticed that the Independent Non-Executive...
Analysis Article Feb 11

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Celebrations may be in order for MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders, with the analysts delivering a...

Revenue & Expenses Breakdown

How Lite Strategy makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:LITS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250-40140
30 Sep 250-12130
30 Jun 250-16140
31 Mar 250-32120
31 Dec 240-38150
30 Sep 240-47200
30 Jun 246518230
31 Mar 246726290
31 Dec 237320310
30 Sep 2310541310
30 Jun 2349-32321
31 Mar 2359-382823
31 Dec 2263-313045
30 Sep 2242-543066
30 Jun 2241-543186
31 Mar 2237-473180
31 Dec 2135-642976
30 Sep 2136-602676
30 Jun 2135-412469
31 Mar 2152-532261
31 Dec 2045-312052
30 Sep 2033-431938
30 Jun 2028-471734
31 Mar 205-241634
31 Dec 195-381634
30 Sep 196-51535
30 Jun 195-171532
31 Mar 194-391329
31 Dec 184-281223
30 Sep 182-461117
30 Jun 182-401017
31 Mar 182-25915
31 Dec 176-20913
30 Sep 1722-2812
30 Jun 1723397
31 Mar 1723199
31 Dec 1618-4811
30 Sep 161-21812
30 Jun 160-21813
31 Mar 160-21813
31 Dec 150-24817
30 Sep 150-28820

Quality Earnings: LITS is currently unprofitable.

Growing Profit Margin: LITS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LITS is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.

Accelerating Growth: Unable to compare LITS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LITS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (31.5%).


Return on Equity

High ROE: LITS has a negative Return on Equity (-48.5%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 12:09
End of Day Share Price 2026/05/13 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lite Strategy, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephen V. ByrneBofA Global Research
Leah Rush CannBrookline Capital Markets
Daniel BrimsCantor Fitzgerald & Co.